During a live event, Pedro Barata, MD, MSc, and participating oncologists discussed how efficacy, tolerability, and clinical evidence inform subsequent-line treatment selection for metastatic clear cell renal cell carcinoma.
|Videos|April 24, 2020
A 61-Year-Old Man With Acute Graft-Versus-Host Disease
Author(s)Usama Gergis, MD
Usama Gergis, MD, presents the case of a 61-year old man with GvHD, and provides an overview of available treatment options for similar patients, with consideration of the REACH1, REACH2, and GRAVITAS-301 trial regimens.
Advertisement
Case Overview:
Initial presentation
- A 61-year old man presented with a generalized pruritic rash, abdominal pain and diarrhea (8-12 BMs/day)
- PMH: he underwent haploidentical allogeneic hematopoietic-cell transplantation for AML 40 days ago
- PE: maculopapular erythematous rash on bilateral palms, cheeks, ears and upper back (rash involvement >50% of skin); abdomen is tender to palpation diffusely
Clinical workup
- Labs: ANC 0.7 x 109/L, plt 75 x 109/L, total bilirubin 8 mg/dl, AST 54 U/L, ALT 60 U/L
- Negative for HBV, HBV, CMV, EBV, HHV-6
- Negative stool tests
- Flexible sigmoidoscopy with biopsy:
- Lower GI biopsy showed moderate mixed inflammation in the lamina propria and scattered apoptotic bodies without crypt loss
- Skin punch biopsy of the back shows hyperkeratosis, hypergranulosis associated with lichenoid inflammatory infiltrate
- Modified Glucksberg criteria: grade 3; MAGIC criteria: grade III
Treatment
- Systemic corticosteroids (prednisone 2 mg/kg/day) + topical steroids (triamcinolone)
- No treatment response after day 5
- He was started on ruxolitinib 5 mg PO BID, increased to 10 mg PO BID on day 6
Advertisement
Related to this article
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
The FDA accepted an sNDA for gedatolisib in PIK3CA-mutant HR+/HER2– advanced breast cancer based on the phase 3 VIKTORIA-1 trial, with a PDUFA date of June 25, 2027.
The FDA grants orphan drug designation to TRX-E-002-1, an investigational small-molecule benzopyran, for the treatment of acute myeloid leukemia (AML).
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Arvind N. Dasari, MD, MS, reviews a year in neuroendocrine tumors marked by expanding radioligand options, improved classification, and disappointing combination therapies.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Accepts sNDA for Gedatolisib in PIK3CA-Mutated HR+/HER2– Breast Cancer
2
COA Backs 340B Payment Cut in 2027 Final Rules, Warns of Physician Cuts
3
Imneskibart Regimens Show Activity in ICI-Refractory Melanoma, NSCLC
4
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
5